Skip to main content
Erschienen in:

01.06.2019 | Case report

Asparaginase/brentuximab-vedotin/dexamethasone

Various toxicities: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Kawamoto K, et al. Safety and effective salvage regimen comprising a novel combination of brentuximab vedotin, L-asparaginase, and dexamethasone for refractory anaplastic large cell lymphoma, anaplastic lymphoma kinase negative. Hematological Oncology 37: 212-214, No. 2, Apr 2019. Available from: URL: http://doi.org/10.1002/hon.2565 - Japan Kawamoto K, et al. Safety and effective salvage regimen comprising a novel combination of brentuximab vedotin, L-asparaginase, and dexamethasone for refractory anaplastic large cell lymphoma, anaplastic lymphoma kinase negative. Hematological Oncology 37: 212-214, No. 2, Apr 2019. Available from: URL: http://​doi.​org/​10.​1002/​hon.​2565 - Japan
Metadaten
Titel
Asparaginase/brentuximab-vedotin/dexamethasone
Various toxicities: case report
Publikationsdatum
01.06.2019
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2019
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-019-63602-8